The authors report that administration 6 months after kidney transplantation of allogeneic bone marrow–derived mesenchymal stromal cells selected to have no repeated HLA mismatches with the kidney donor was safe 1 year after transplantation with no instances of biopsy‐proven acute rejection, graft loss, or de novo antibodies against either donor.
All Keywords
【저자키워드】 stem cells, clinical trial, immune regulation, clinical research/practice, immunosuppression/immune modulation, kidney transplantation/nephrology, monitoring: immune,
【저자키워드】 stem cells, clinical trial, immune regulation, clinical research/practice, immunosuppression/immune modulation, kidney transplantation/nephrology, monitoring: immune,